{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T21:49:24Z","timestamp":1791582564277,"version":"4.3.4"},"reference-count":25,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>We hypothesized that the presence of monoclonal free kappa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS), as detected by the serum free light chain (FLC) assay increases the risk of progression to malignancy. Of 1384 patients with MGUS from Southeastern Minnesota seen at the Mayo Clinic from 1960 to 1994, baseline serum samples obtained within 30 days of diagnosis were available in 1148. At a median follow-up of 15 years, malignant progression had occurred in 87 (7.6%) patients. An abnormal FLC ratio (kappa-lambda ratio &amp;lt; 0.26 or &amp;gt; 1.65) was detected in 379 (33%) patients. The risk of progression in patients with an abnormal FLC ratio was significantly higher compared with patients with a normal ratio (hazard ratio, 3.5; 95% confidence interval [CI], 2.3-5.5; P &amp;lt; .001) and was independent of the size and type of the serum monoclonal (M) protein. Patients with an abnormal serum FLC ratio, non\u2013immunoglobulin G (non-IgG) MGUS, and a high serum M protein level (\u2265 15 g\/L) had a risk of progression at 20 years of 58% (high-risk MGUS) versus 37% with any 2 of these risk factors (high-intermediate risk), 21% with one risk factor (low-intermediate risk), and 5% when none of the risk factors were present (low risk).<\/jats:p>","DOI":"10.1182\/blood-2005-03-1038","type":"journal-article","created":{"date-parts":[[2005,4,26]],"date-time":"2005-04-26T23:09:26Z","timestamp":1114556966000},"page":"812-817","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":594,"title":["Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance"],"prefix":"10.1182","volume":"106","author":[{"given":"S. Vincent","family":"Rajkumar","sequence":"first","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry M.","family":"Therneau","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"L. Joseph","family":"Melton","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur R.","family":"Bradwell","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raynell J.","family":"Clark","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk R.","family":"Larson","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew F.","family":"Plevak","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jerry A.","family":"Katzmann","sequence":"additional","affiliation":[{"name":"From the Division of Hematology, Department of Laboratory Medicine and Pathology, Division of Biostatistics and Division of Epidemiology, Mayo Clinic College of Medicine, Rochester, MN; University of Birmingham and The Binding Site Ltd, Birmingham, United Kingdom."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2020021223185198500_REF1","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance (MGUS) among Olmsted County, MN residents 50 years of age [abstract]. Blood. 2003;102: 934a. Abstract A3476."},{"key":"2020021223185198500_REF2","doi-asserted-by":"crossref","unstructured":"The International Myeloma Working Group. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121: 749-757.","DOI":"10.1046\/j.1365-2141.2003.04355.x"},{"key":"2020021223185198500_","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Dispenzieri A, Fonseca R, et al. Thalidomide for previously untreated indolent or smoldering multiple myeloma. Leukemia. 2001;15: 1274-1276.","DOI":"10.1038\/sj.leu.2402183"},{"key":"2020021223185198500_REF4","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Monoclonal gammopathies of undetermined significance. Hematol Oncol Clin North Am. 1999;13: 1181-1202.","DOI":"10.1016\/S0889-8588(05)70120-9"},{"key":"2020021223185198500_REF5","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, et al. A long-term study of prognosis of monoclonal gammopathy of undetermined significance. N Engl J Med. 2002;346: 564-569.","DOI":"10.1056\/NEJMoa01133202"},{"key":"2020021223185198500_REF6","doi-asserted-by":"crossref","unstructured":"Kyle RA, Therneau TM, Rajkumar SV, Larson DR, Plevak MF, Melton LJ 3rd. Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later [see comment]. Mayo Clin Proc. 2004;79: 859-866.","DOI":"10.4065\/79.7.859"},{"key":"2020021223185198500_REF7","doi-asserted-by":"crossref","unstructured":"Kyle RA. \u201cBenign\u201d monoclonal gammopathy\u2014after 20 to 35 years of follow-up. Mayo Clin Proc. 1993;68: 26-36.","DOI":"10.1016\/S0025-6196(12)60015-9"},{"key":"2020021223185198500_REF8","doi-asserted-by":"crossref","unstructured":"Kyle RA, Rajkumar SV. Multiple Myeloma. N Engl J Med2004;351: 1860-1873.","DOI":"10.1056\/NEJMra041875"},{"key":"2020021223185198500_","doi-asserted-by":"crossref","unstructured":"Kyle RA, Gertz MA, Witzig TE, et al. Review of 1,027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proc. 2003;78: 21-33.","DOI":"10.4065\/78.1.21"},{"key":"2020021223185198500_REF10","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc. 2002;77: 813-822.","DOI":"10.4065\/77.8.813"},{"key":"2020021223185198500_REF11","doi-asserted-by":"crossref","unstructured":"Cesana C, Klersy C, Barbarano L, et al. Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. J Clin Oncol. 2002;20: 1625-1634.","DOI":"10.1200\/JCO.20.6.1625"},{"key":"2020021223185198500_REF12","doi-asserted-by":"crossref","unstructured":"Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97: 2900-2902.","DOI":"10.1182\/blood.V97.9.2900"},{"key":"2020021223185198500_REF13","doi-asserted-by":"crossref","unstructured":"Katzmann JA, Clark RJ, Abraham RS, et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem. 2002;48: 1437-1444.","DOI":"10.1093\/clinchem\/48.9.1437"},{"key":"2020021223185198500_REF14","doi-asserted-by":"crossref","unstructured":"Bradwell AR, Carr-Smith HD, Mead GP, Harvey TC, Drayson MT. Serum test for assessment of patients with Bence Jones myeloma. Lancet. 2003;361: 489-491.","DOI":"10.1016\/S0140-6736(03)12457-9"},{"key":"2020021223185198500_REF15","doi-asserted-by":"crossref","unstructured":"Lachmann HJ, Gallimore R, Gillmore JD, et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br J Haematol. 2003;122: 78-84.","DOI":"10.1046\/j.1365-2141.2003.04433.x"},{"key":"2020021223185198500_REF16","doi-asserted-by":"crossref","unstructured":"Abraham RS, Clark RJ, Bryant SC, et al. Correlation of serum immunoglobulin free light chain quantification with urinary Bence Jones protein in light chain myeloma. Clin Chem. 2002;48: 655-657.","DOI":"10.1093\/clinchem\/48.4.655"},{"key":"2020021223185198500_REF17","unstructured":"Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer, 2000: 102-111."},{"key":"2020021223185198500_REF18","doi-asserted-by":"crossref","unstructured":"Cox DR. Regression models and life tables. J R Stat Soc (B). 1972;34: 187-202.","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"2020021223185198500_REF19","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53: 457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"2020021223185198500_REF20","doi-asserted-by":"crossref","unstructured":"Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine. 1999;18: 695-706.","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O"},{"key":"2020021223185198500_REF21","doi-asserted-by":"crossref","unstructured":"Kyle RA. Monoclonal gammopathy of undetermined significance: natural history in 241 cases. Am J Med. 1978;64: 814-826.","DOI":"10.1016\/0002-9343(78)90522-3"},{"key":"2020021223185198500_REF22","doi-asserted-by":"crossref","unstructured":"Rajkumar SV, Kyle RA, Therneau TM, et al. Presence of monoclonal free light chains in the serum predicts risk of progression in monoclonal gammopathy of undetermined significance (MGUS). Br J Haematol. 2004;127: 308-310.","DOI":"10.1111\/j.1365-2141.2004.05169.x"},{"key":"2020021223185198500_REF23","doi-asserted-by":"crossref","unstructured":"Kyle RA, Beard CM, O'Fallon WM, Kurland LT. Incidence of multiple myeloma in Olmsted County, Minnesota: 1978 through 1990, with a review of the trend since 1945. J Clin Oncol. 1994;12: 1577-1583.","DOI":"10.1200\/JCO.1994.12.8.1577"},{"key":"2020021223185198500_REF24","doi-asserted-by":"crossref","unstructured":"Szczepanski T, van `t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(-) subgroup of multiple myeloma. Blood. 2000;96: 1087-1093.","DOI":"10.1182\/blood.V96.3.1087"},{"key":"2020021223185198500_REF25","unstructured":"Rajkumar SV, Kyle RA. Conventional therapy and approach to management. Best Pract Res Cl Ha. In press."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/812\/1712035\/zh801505000812.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/106\/3\/812\/1712035\/zh801505000812.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T17:44:02Z","timestamp":1625852642000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/106\/3\/812\/21884\/Serum-free-light-chain-ratio-is-an-independent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,1]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,8,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2005-03-1038","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,1]]}}}